Skip to content

Amylyx Pharmaceuticals, Inc. AMLX Prepaid & Other Current

Prepaid & Other Current at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$8.56M+145%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.22M+41.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$55.3M+99.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$22.36M+36.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$46.59M+10.2%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$26.62M+50.8%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.89B+390%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0.0×
Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s prepaid & other current?
Amylyx Pharmaceuticals, Inc. (AMLX) reported prepaid & other current of $5.26M in Q1 2026.
How has Amylyx Pharmaceuticals, Inc.'s prepaid & other current changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s prepaid & other current decreased by 55.4% year-over-year, from $11.78M to $5.26M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s prepaid & other current?
Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s prepaid & other current has grown at a 47.3% compound annual growth rate (CAGR), from $7.16M to $33.69M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.